Table 4.
OA treatments administered
| Treatment | Details | Number (%) | Monotherapy (%) |
|---|---|---|---|
| DMOADsa | 35 (71%) | 17 (59%) | |
| Injectable PSGAGsb | |||
| Injectable pentosan PSc | |||
| Oral glucosamine supplement | |||
| NSAIDsd | 16 (33%) | 8 (28%) | |
| Meloxicam | |||
| Tolfenamic acid | |||
| Dietary therapy | MediCal Mobility Support® | 12 (24%) | 4 (14%) |
| Other | Gabapentin | 3 (6%) | 0 |
| Glucocorticoids | 3 (6%) | 0 | |
| Laser | 1 (2%) | 0 | |
| Herbal supplement | 1 (2%) | 0 |
For specific treatments, percentages shown are of the total number treated (Number) or of the total number treated with a single agent (Monotherapy).
a
DMOADs — Disease-modifying osteoarthritis drugs
b
PSGAGs — Polysulfated glycosaminoglycans (Adequan®; Novartis Animal Health, Mississauga, Ontario).
c
Pentosan PS — Pentosan polysulfate (Cartrophen Vet; Arthropharm Services, Embrun, Ontario).
d
NSAID — Non-steroidal anti-inflammatory drug.